FINWIRES · TerminalLIVE
FINWIRES

HKG:2367

2 stories mentioning HKG:2367Updated just now

Every FINWIRES story that references HKG:2367, newest first.

Research

China Merchants Securities Downgrades Giant Biogene to Sell from Hold; Price Target is HK$25

Giant Biogene Holding (HKG:2367) has an average rating of overweight and mean price target of HK$37.14, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

HKG:2367
Asia

Giant Biogene Unit Gets Registration Certificate for Neck Wrinkle Injection

Giant Biogene (HKG:2367) unit Shaanxi Giant Biotechnology obtained a medical device registration certificate for its cross-linked recombinant collagen implant from China's National Medical Products Administration.The drug is intended for intradermal injection into the dermis layer of the neck to correct moderate to severe horizontal neck wrinkles, according to a Wednesday Hong Kong bourse filing.

HKG:2367

Track with the FINWIRES app suite

FolioX
FolioX
Track HKG:2367 in your portfolio
WheelAI
WheelAI
Analyze HKG:2367 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on HKG:2367